Wolfe Research Initiates Coverage On Genmab with Outperform Rating, Announces Price Target of $32

Benzinga Newsdesk www.benzinga.com Positive 55.0%

Neg 0% Neu 0% Pos 55%

Wolfe Research analyst Kalpit Patel initiates coverage on Genmab (NASDAQ:GMAB) with a Outperform rating and announces Price Target of $32.